PT Kimia Farma Tbk won an award in the 2024 West Java Innovation Competition (KIJB) organized by the West Java Regional Research and Development Agency (BP2D) on Thursday, November 21, 2024 in Bandung. The award was given to Kimia Farma which produced innovations in the health sector, namely the JABAR BEDAS (West Java Free from HIV/AIDS) program to overcome problems related to the high prevalence of HIV/AIDS cases in West Java and the SEIKAT RANTING (An Innovation in Healthy Food Anti-Stunting Sprinkles) - New Taburia program to overcome problems related to the high prevalence of stunting cases in West Java. The award was presented by the Acting Governor of West Java, Bey Triadi Machmudin to Jasmine K. Karsono as Director of Portfolio, Products and Services of Kimia Farma.
"We would like to thank Kimia Farma for the award given. The company always encourages innovations in the health sector, so that it can provide real benefits and impacts for the community," said Jasmine.
KIJB is a commitment from the West Java Provincial Government to improve the culture of innovation while providing appreciation to innovators. Kimia Farma competed with 1,219 innovation participants within the scope of the West Java Provincial Government, Regency and City Governments throughout West Java, Centers, Ministry Bureaus, Institutions, Universities, BUMN and BUMD in West Java which took place from July 2024 to November 2024. Innovation assessments include ideas, renewal methods, contributions to development achievements/strategic issues, adaptability, sustainability, goals, benefits, and innovation results. The JABAR BEDAS program won the top 3 for the best innovation in the BUMN/BUMD category as an innovative solution to assist the government in improving and expanding public access to HIV/AIDS screening, diagnostic, and treatment services. The JABAR BEDAS program consists of 2 subprograms, the first is a program as a preventive effort through early detection using kifatest, a local HIV rapid test kit product with 100% test sensitivity and specificity according to WHO standards. Second, as a program as a curative effort through fixed dose Combination Antiretroviral (ARV) tablets with three active ingredients Efavirenz, Lamivudine, and Tenofovir (ELT). ELT medicine is the first copy combination medicine in Indonesia that uses domestic raw materials. ELT medicine can help to increase compliance and provide convenience to patients, so that patients only need to consume 1 tablet with three active ingredients in it. In addition, SEIKAT RANTING - New Taburia won the top 5 for innovation in the BUMN/BUMD JABAR category. This program is a form of anti-stunting prevention by providing sprinkles containing 22 micronutrients including vitamins and minerals that are useful as supporting macronutrient nutrition during the Complementary Food for Breast Milk (MPASI) period for children aged 6-23 months. This innovation is an innovation from the Taburia product which previously only contained 16 micronutrients. This program can be collaborated with the West Java Province Stunting Prevalence Reduction Team (TPPS) for curative efforts to support the reduction in the incidence of stunting and preventive efforts to prevent the emergence of new cases of stunting in infants under 2 years old. It is hoped that this program can have a real impact in efforts to create the generation of Golden Indonesia 2045.
"Through this event, it is one of the motivations for Kimia Farma through the research and development team to always create product innovations by utilizing increasingly developing technology, which can provide solutions to health problems in Indonesia. This is our commitment to continue to be in line with and support the Government in realizing health resilience in Indonesia," concluded Jasmine.